



Cancer Immunology: From Molecular Mechanisms to Therapeutic Target through Emerging In Vitro Approaches

Guest Editor:

Dr. Silvia Scaglione

1. React4life SRL, 16121 Genova, Italy
2. National Research Council of Italy, Institute of Electronics, Information Engineering and Telecommunications (IEIIT), 16149 Genova, Italy

Deadline for manuscript
submissions:
closed (29 February 2024)

Message from the Guest Editor

In recent years, cancer immunotherapy has emerged as a promising therapeutic strategy to improve the treatment and benefits of individual patients. However, mechanisms behind tumor immunogenicity, immune cell invasion, adaptive immune responses against cancer, and escape mechanisms are still not completely elucidated.

In this context, the availability of more reliable preclinical models capable of recapitulating the real complexity of the human tumor microenvironment while overcoming the limitations of traditional approaches becomes mandatory. In particular, it is important to find ways to evolve current in vitro/in vivo models to become more predictive of the human patient heterogeneity and response to testing therapies.

This Special Issue will focus on translational research aimed at discussing the main challenges and possible future trends of cancer immunotherapies, by deepening novel and emerging in vitro approaches, such as immune component 3D tumor models, organ-on-chip technologies, tumor organoids, and 3D bioprinting.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI